Indications for implantable cardiac defibrillators in patients with congestive heart failure: Implicatons of the sudden cardiac death in heart failure trial

被引：0

作者：

Pourati I. ^{[1
]}

Hyder M. ^{[1
]}

Rosenthal L. ^{[1
]}

机构：

[1] Department of Medicine, The Division of Cardiovascular Medicine, UMass Memorial Medical Center, Worcester, MA 01655

来源：

Current Cardiology Reports | 2005年 / 7卷 / 3期

关键词：

Amiodarone; Ventricular Tachycardia; Implantable Defibrillator; Nonischemic Cardiomyopathy; Multicenter Automatic Defibrillator Implantation Trial;

D O I：

10.1007/s11886-005-0081-8

中图分类号：

学科分类号：

摘要：

Sudden cardiac death (SCD) is a significant cause of mortality in patients suffering from heart failure and left ventricular dysfunction. Implantable cardioverter defibrillators have been shown to effectively reduce the incidence of SCD in this population. Recent clinical trials have redefined the indications and patient profiles for their use: from secondary prevention to primary prevention of SCD. In this article, we review the clinical trials contributing to the current practice guidelines, which include device therapy. Copyright © 2005 by Current Science Inc.

引用

页码：223 / 228

页数：5

共 24 条

[11]

Bigger Jr. J.T., Fleiss J.L., Kleiger R., Et al., The relationships among ventricular arrhythmias, left ventricular dysfunction, and mortality in the 2 years after myocardial infarction, Circulation, 69, pp. 250-258, (1984)

[12]

Singh S.N., Fletcher R.D., Fisher S.G., Et al., Amiodarone in patients with congestive heart failure and asymptomatic ventricular arrhythmia. Survival Trial of Antiarrhythmic Therapy in Congestive Heart Failure, N. Engl. J. Med., 333, pp. 121-122, (1995)

[13]

Wilber D.J., Olshansky B., Moran J.F., Scanlon P.J., Electrophysiological testing and nonsustained ventricular tachycardia. Use and limitations in patients with coronary artery disease and impaired ventricular function, Circulation, 82, pp. 633-635, (1990)

[14]

Moss A.J., Hall W.J., Cannom D.S., Et al., Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia. Multicenter Automatic Defibrillator Implantation Trial Investigators, N. Engl. J. Med., 335, pp. 1933-1940, (1996)

[15]

Buxton A.E., Lee K.L., Fisher J.D., Et al., A randomized study of the prevention of sudden death in patients with coronary artery disease. Multicenter Unsustained Tachycardia Trial Investigators, N. Engl. J. Med., 335, pp. 1933-1940, (1996)

[16]

Moss A.J., Zareba W., Hall W.J., Klein H., Et al., Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction, N. Engl. J. Med., 346, pp. 877-883, (2002)

[17]

Klein H., Auricchio A., Reek S., Geller C., New primary prevention trials of sudden cardiac death in patients with left ventricular dysfunction: SCD-HEFT and MADIT-II, Am. J. Cardiol., 83, (1999)

[18]

Burdy G.H., SCD-HEFT Results. Presented at the American College of Cardiology, (2004)

[19]

Kadish A., Dyer A., Daubert J.P., Et al., Prophylactic defibrillator implantation in patients with nonischemic dilated cardiomyopathy, N. Engl. J. Med., 350, pp. 2151-2158, (2004)

[20]

Bristow M., Saxon L., Boehmer J., Et al., Cardiac-resynchronization therapy with or without an implantable defibrillator advanced chronic heart failure, N. Engl. J. Med., 350, pp. 2140-2150, (2004)

← 1 2 3 →